clinical trial · NCT07122076
GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases
Grit Biotechnology·early phase1·recruiting·n = 10
Autoimmune DiseasesGT719 Injection
brief summary
This study is a prospective single-arm open-label clinical trial, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in patients with moderate to severe refractory autoimmune diseases. A total of 10 subjects will be enrolled in this study.
started
Aug 22, 2025
primary completion
Aug 21, 2028
completion
Aug 21, 2028
last updated
Sep 22, 2025
official title
A Single-arm, Open-label Clinical Study of GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol